MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

AstraZeneca PLC ADR

Uždarymo kaina

72.55 -1.25

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

72.4

Max

73.83

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-162M

1.7B

Pardavimai

1.3B

15B

P/E

Sektoriaus vid.

32.929

73.239

Pelnas, tenkantis vienai akcijai

1.045

Dividendų pajamingumas

2.09

Pelno marža

11.188

Darbuotojai

94,300

EBITDA

330M

4.4B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+26.28% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.09%

3.06%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

233B

Ankstesnė atidarymo kaina

73.8

Ankstesnė uždarymo kaina

72.55

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

AstraZeneca PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-24 03:15; UTC

Pagrindinės rinkos jėgos

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

2025-03-17 07:42; UTC

Įsigijimai, susijungimai, perėmimai

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

2025-02-06 11:07; UTC

Uždarbis

AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China -- Update

2025-03-31 09:31; UTC

Karštos akcijos

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

2025-03-17 14:43; UTC

Rinkos pokalbiai

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

2025-03-17 13:55; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

2025-03-17 07:04; UTC

Įsigijimai, susijungimai, perėmimai

AstraZeneca: Transaction Doesn't Affect Fincl Guidance for 2025.

2025-03-17 07:03; UTC

Įsigijimai, susijungimai, perėmimai

AstraZeneca: Acquisition Expected to Close in 2Q 2025

2025-03-17 07:03; UTC

Įsigijimai, susijungimai, perėmimai

AstraZeneca to Pay Up to $575M Upon Development, Regulatory Milestones Being Met

2025-03-17 07:01; UTC

Įsigijimai, susijungimai, perėmimai

AstraZeneca to Make Initial Payment of $425M on Deal Closing

2025-03-17 07:01; UTC

Įsigijimai, susijungimai, perėmimai

AstraZeneca Buying EsoBiotec for up to $1B

2025-03-17 07:01; UTC

Įsigijimai, susijungimai, perėmimai

AstraZeneca to Buy EsoBiotec to Advance Cell Therapy Ambition

2025-03-17 07:00; UTC

Įsigijimai, susijungimai, perėmimai

AstraZeneca to Buy EsoBiotec

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-26 14:59; UTC

Rinkos pokalbiai

AstraZeneca's Breast-Cancer Drug Results Seen as Positive Surprise -- Market Talk

2025-02-26 08:04; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

2025-02-20 11:34; UTC

Įsigijimai, susijungimai, perėmimai

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

2025-02-20 11:34; UTC

Įsigijimai, susijungimai, perėmimai

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

2025-02-20 11:33; UTC

Įsigijimai, susijungimai, perėmimai

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

2025-02-20 11:33; UTC

Įsigijimai, susijungimai, perėmimai

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

2025-02-20 11:31; UTC

Įsigijimai, susijungimai, perėmimai

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

2025-02-20 11:30; UTC

Įsigijimai, susijungimai, perėmimai

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

2025-02-13 10:49; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk

2025-02-07 10:30; UTC

Svarbiausios naujienos

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

2025-02-06 15:18; UTC

Rinkos pokalbiai

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

2025-02-06 13:24; UTC

Rinkos pokalbiai

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

2025-02-06 12:01; UTC

Uždarbis

Global Stocks in Spotlight: BYD, Kering, Maersk -- WSJ

2025-02-06 11:22; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca's Sales Beat, Pipeline Outshines Margin Miss -- Market Talk

2025-02-06 11:18; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca's Outlook Makes Midterm Target Look Achievable -- Market Talk

2025-02-06 11:02; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca's China Woes Seem Manageable -- Market Talk

Akcijų palyginimas

Kainos pokytis

AstraZeneca PLC ADR Prognozė

Kainos tikslas

By TipRanks

26.28% į viršų

12 mėnesių prognozė

Vidutinis 93.18 USD  26.28%

Aukščiausias 98 USD

Žemiausias 88 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AstraZeneca PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

73.05 / 77.08Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.